PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences: Piper Sandler Healthcare Conference, New York, NY: Fireside Chat on Tuesday, December 2 at 10:30 am ESTEvercoreISI HealthCONx Conference, Miami, FL: Fireside Chat on Wednesday, Decemb ...

Core Insights - BridgeBio Pharma, Inc. is set to release its second quarter financial results and business updates on August 5, 2025, after market close [1] - A conference call will be held at 4:30 pm ET on the same day to discuss the financial results and program updates [1] Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases [3] - The company was founded in 2015 and has a pipeline that includes programs from early science to advanced clinical trials [3] - BridgeBio's team consists of experienced professionals dedicated to applying advances in genetic medicine to benefit patients [3]